Wenqi Jiang

Find an error

Name:
Organization: Shenzhen University
Department:
Title:
Co-reporter:Dong Gao, Yu Liu, Yuwen Diao, Ningning Gao, Zhulin Wang, Wenqi Jiang, and Guangyi Jin
ACS Medicinal Chemistry Letters 2015 Volume 6(Issue 3) pp:249
Publication Date(Web):January 30, 2015
DOI:10.1021/ml5003647
During the design and synthesis of a series of 8-hydroxy-2-(2-methoxyethoxy)-adenine derivatives bearing various substituted −RCOOH groups at the 9-position, we identified a TLR7-inert ligand, which does not activate TLR7 signaling pathway. Of interest, the coupling of weakly immunogenic antigens via the −RCOOH group was able to significantly enhance the immunogenicity of the antigens. Herein, an inert ligand, 9-(3-carboxypropyl)-8-hydroxy-2-(2-methoxyethoxy)-adenine (5, GD2), was synthesized and conjugated to 5 different weakly immunogenic antigens (BSA, OVA, MSA, MG7, and thymosin). Compared with the GD2 and the potent agonist UC-1 V150, all conjugates demonstrated potent immunogenicity in vitro and in vivo. All conjugates induced prolonged increases, while UC-1 V150 showed a rapid decline in the levels of proinflammatory cytokines following initial increases. These data indicate that the immunostimulatory activity of TLR7-inert ligands could be amplified and prolonged by conjugation to antigens, thus broadening the potential therapeutic application of these agents.Keywords: adenine derivative; immunostimulatory activity; Toll-like receptor agonist
Co-reporter:Dong Gao, Yu Liu, Wang Li, Fangshu Zhong, Xiaoli Zhang, Yuwen Diao, Ningning Gao, Xiaodong Wang, Wenqi Jiang, Guangyi Jin
Bioorganic & Medicinal Chemistry Letters 2014 Volume 24(Issue 24) pp:5792-5795
Publication Date(Web):15 December 2014
DOI:10.1016/j.bmcl.2014.10.034
Co-reporter:Ou Sha;Junfei Niu;Tzi-Bun Ng;Eric Yu-Pang Cho;Xiaoyuan Fu;Wenqi Jiang
Cancer Chemotherapy and Pharmacology 2013 Volume 71( Issue 6) pp:1387-1393
Publication Date(Web):2013/06/01
DOI:10.1007/s00280-013-2096-y
Trichosanthin (TCS) as a midterm abortifacient medicine has been used clinically in traditional Chinese medicine for centuries. Additionally, TCS manifests a host of pharmacological properties, for instance, anti-HIV and anti-tumor activities. TCS has been reported to inhibit cell growth of a diversity of cancers, including cervical cancer, choriocarcinoma, and leukemia/lymphoma, etc. This article purported to review the various anti-tumor activities of TCS and the mechanism of apoptosis it induced in these tumor cells. These research progresses provide an insight into cancer research and treatment as well as disclose new pharmacological properties of the ancient but popular Chinese medicine.
Co-reporter:Haihui Wu, Meiqi Zeng, Eric Y.P Cho, Wenqi Jiang, Ou Sha
Progress in Histochemistry and Cytochemistry (July 2015) Volume 50(Issues 1–2) pp:11-17
Publication Date(Web):1 July 2015
DOI:10.1016/j.proghi.2015.06.001
•MrgX2 is selectively expressed in the small-diameter sensory neurons and mast cells.•By positive selection, MrgX2 has undergone adaptive changes in the human evolution.•MRGX2 can interact with various factors: cortistatin, LL-37, β-defensins, et al.•Research on MrgX2 provides insights into its role in the nociception and immunity.•The detailed mechanism of MRGX2 signal transduction needs further studies.Mas-related genes (Mrgs) belong to a large family of G protein-coupled receptor genes found in rodents. Human MRGX proteins are G protein-coupled 7-transmembrane proteins sharing 41-52% amino acid identity with each other, but have no orthologs in rodents. MrgX2 is a member of the MrgX family. MRGX2 is expressed in the small neurons of sensory ganglia and mast cells. It can interact with a series of factors and genes such as the peptides substance P, vasoactive intestinal peptide, cortistatin (CST), proadrenomedullin N-terminal peptide (PAMP), LL-37, PMX-53 and β-defensins. MRGX2 is related to nociception, adrenal gland secretion and mast cell degranulation. Recent research on MrgX2 provides insights into its role in nociception and anti-microbial activities. This article reviewed the origin, expression and function of MrgX2, and discussed possible future research focus.
ceritinib
1-[4-AMINO-2-(ETHYLAMINOMETHYL)IMIDAZO[4,5-C]QUINOLIN-1-YL]-2-METHYLPROPAN-2-OL
Nilotinib & its intermediates
Pazopanib
Glycogen synthase kinase 3, GSK3β
Thiazolo[4,5-d]pyrimidine-2,7(3H,4H)-dione,5-amino-3-b-D-ribofuranosyl-
Guanosine,7,8-dihydro-8-oxo-7-(2-propen-1-yl)-
Protein tyrosine kinase
Substance P